New pill tested in fight against tough cancers

NCT ID NCT03363893

Completed Disease control Sponsor: Carrick Therapeutics Limited Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested the safety and side effects of a new oral drug called CT7001 in people with advanced solid tumors that had stopped responding to standard treatments. It involved 124 participants and looked at CT7001 given alone and in combination with other cancer therapies, specifically for certain types of breast and prostate cancer. The main goal was to find safe dose levels and understand how the body processes the drug.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site 1

Manchester, M20 4BX, United Kingdom
Research Site 10

Liverpool, L69 3BX, United Kingdom
Research Site 2

Oxford, OX3 7LE, United Kingdom
Research Site 3

London, W2 1NY, United Kingdom
Research Site 31

Beverly Hills, California, 90211, United States
Research Site 33

Salem, Virginia, 24153, United States
Research Site 34

Boston, Massachusetts, 02215, United States
Research Site 36

Portland, Oregon, 97239, United States
Research Site 37

Tampa, Florida, 33612, United States
Research Site 38

Chicago, Illinois, 60611, United States
Research Site 39

Columbus, Ohio, 43212, United States
Research Site 4

Manchester, M20 4BX, United Kingdom
Research Site 44

Austin, Texas, 78705, United States
Research Site 46

Dallas, Texas, 75246, United States
Research Site 47

Cincinnati, Ohio, 45236, United States
Research Site 48

Salt Lake City, Utah, 84112, United States
Research Site 54

Tucson, Arizona, 85719, United States
Research Site 6

Southampton, SO16 6YD, United Kingdom
Research Site 7

Glasgow, G12 0YN, United Kingdom
Research Site 8

London, W1G 6AD, United Kingdom
Research Site 9

London, SE1 9RT, United Kingdom
Research site 11

Brighton, BN2 5BE, United Kingdom
Research site 5

Cambridge, CB2 0QQ, United Kingdom

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID MALIGNANCIES